🇺🇸 FDA
Patent

US 7517527

Immunotoxin with in vivo T cell suppressant activity and methods of use

granted A61KA61K2039/505A61K47/6829

Quick answer

US patent 7517527 (Immunotoxin with in vivo T cell suppressant activity and methods of use) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K2039/505, A61K47/6829, A61K47/6849